| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | KIN001-135 | GDSC1000 | pan-cancer | AAC | -0.046 | 0.5 |
| mRNA | Compound 1541A | CTRPv2 | pan-cancer | AAC | 0.031 | 0.5 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | 0.045 | 0.5 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | 0.041 | 0.5 |
| mRNA | Sorafenib | FIMM | pan-cancer | AAC | 0.13 | 0.5 |
| mRNA | BRD-K50799972 | CTRPv2 | pan-cancer | AAC | 0.03 | 0.5 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | 0.028 | 0.5 |
| mRNA | temsirolimus | GDSC1000 | pan-cancer | AAC | -0.026 | 0.5 |
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | -0.035 | 0.5 |
| mRNA | PD-0332991 | FIMM | pan-cancer | AAC | -0.12 | 0.5 |